LEADCAPITAL-MARKETS
11.10.2016 18:23:32 CEST | Business Wire | Press release
Fresh on the market is the latest brand from Leadcapital Markets; TRADE.com. The team has invested massively into a new platform designed to compete with MT4 and bring an innovative approach to dealing.
Launching the new site, TRADE.com VP of marketing, Roei Gavish says, “Our work with IBs and affiliates has allowed us to develop the new WebTrader to be more intuitive, with powerful analytic programs alongside over 2,000 CFD instruments across six asset classes. We believe that a new way of trading online is finally here, with a simpler platform, tighter regulation, relevant resources.”
“We are going to great lengths to ensure that traders have all the information they need to make intelligent decisions,” Gavish continues as he refers to the daily outlook video specifically recorded for pre-session market movements, plus the real-time news coverage and 5 Levels of education.
This active approach to online trading is backed up with a global branding campaign, going live in the fourth quarter of 2016. Gavish says, “We intend to spread our story as a company who looked at trading differently and took it to the next level; to open up to people from all walks of life, 24/7, from around the globe.”
Branded with the slogan, ‘Anyone, Anytime, Anywhere’, TRADE.com has expanded its traditional territories of Asia, mainland Europe and the Middle East to the thriving Scandinavian regions, now with 24 languages online. However, access for the masses to transparent trading does not stop at translations as TRADE.com also provides apps for download to use on all devices, fulfilling the ‘anytime, anywhere’ element of the brand.
Of course, with any new brand the market will always question credentials and regulation, which is why Leadcapital Markets employed a compliance team specifically to take on the regulation for the TRADE.com brand. Among the tasks was to ensure that the company was registered on every one of the 27 European cross border service regulators. Roei Gavish commented, “We insist on compliance that fulfills modern day needs and by keeping up to date with a dedicated team, we can give confidence to all our clients to trade safely and positively.”
TRADE.com is CySec regulated and is the brand of LeadCapital Markets.
website: www.trade.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20161011006374/en/
Contact:
Leadcapital Markets
Roei Gavish
support@trade.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Serviceplan Group Deploys Creative AI Across Global Operations in Partnership With Luma AI19.2.2026 11:00:00 CET | Press release
Serviceplan Group becomes the first of the world’s largest agency groups to standardize AI for creative work across professional workflows at scale, strengthening productivity and long-term competitiveness. Serviceplan Group today announced a strategic partnership with Luma AI to deploy AI for creative work across the agency group’s global operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219346568/en/ Serviceplan Group today announced a strategic partnership with Luma AI to deploy AI for creative work across the agency group’s global operations. Shown here (L-R) Alex Schill, Global Chief Creative Officer of Serviceplan Group, Jason Day, Head of EMEA for Luma AI, Amit Jain, Co-Founder and CEO of Luma AI, and Florian Haller, CEO of Serviceplan Group. Under the agreement, Luma AI will serve as Serviceplan Group’s AI technology partner, embedding AI for creative work into professional workflows spanning strategy, cr
GekkoVet and Royal Canin Enter Latin America with Mexico Launch, Opening a New Continent in their Global Partnership19.2.2026 10:59:00 CET | Press release
GekkoVet, the Finnish leader in AI-powered clinical decision support for veterinarians, and Royal Canin, a global pioneer in pet health through nutrition, announce the launch of their strategic collaboration in Mexico. This marks the first national rollout of their partnership in Latin America, expanding the initiative that began earlier this year with successful deployments in Asia. Royal Canin Mexico is equipping veterinary teams with GekkoVet’s intelligent platform, which provides real-time diagnostic assistance, treatment recommendations, and drug information. The collaboration aims to enhance clinical efficiency, improve patient outcomes, and support veterinarians with evidence-based tools that integrate seamlessly into daily practice. “This launch in Mexico is a major step forward—not just regionally, but globally,” said Johanna Majamaa, DVM and co-founder of GekkoVet. “After strong momentum in Asia, entering Latin America opens a new chapter in our mission to empower veterinaria
Vonage Expands Developer Ecosystem to Accelerate the Next Era of Enterprise Digital Transformation19.2.2026 10:08:00 CET | Press release
Vonage verified Postman workspace extends reach by 40+ million developers; MCP servers and Startup Program among resources designed to further accelerate time-to-value for developers and enterprises Vonage, part of Ericsson (NASDAQ: ERIC), today announced a number of new initiatives, to further expand and enable its global developer community. By growing its developer community and tools, giving developers and enterprises access to new mobile network insights and capabilities that can be embedded into existing applications and workflows, Vonage is accelerating its strategy to transform mobile networks into a programmable platform. Putting Vonage APIs in the Hands of 40 million+ More Developers Vonage is announcing the launch of its Verified Workspace on the Postman API Network, making Vonage APIs available to the 40+ million developers who use Postman. The new, verified workspace gives Postman’s community of global developer members certified access to Vonage’s portfolio of Network API
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 08:50:00 CET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 08:30:00 CET | Press release
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom